NCT05597527 2022-10-28
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Fujian Cancer Hospital
Phase 2 Unknown
Clinical Trials
15 trialsNCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04974944 2021-10-01
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04068974 2021-03-16
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04590625 2020-10-19
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT03475589 2020-05-12
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
Sun Yat-sen University
Phase 4 Unknown
NCT04383977 2020-05-12
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03546855 2018-06-06
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
Anhui Provincial Hospital
Phase 2 Unknown
NCT03547375 2018-06-06
Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy
Anhui Provincial Hospital
Phase 2 Unknown
NCT03393507 2018-01-16
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
The People's Hospital of Leshan
Phase 2 Unknown
NCT03298074 2017-09-29
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer
Guangxi Medical University
Phase 2 Unknown
NCT03262545 2017-08-28
Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03029013 2017-01-23
Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer
Third Military Medical University
Phase NA Unknown